- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07947069
Nebulized Plus Intravenous Versus Intravenous Furosemide in Pulmonary Edema
Effectiveness of Nebulized Plus Intravenous Furosemide Versus Intravenous Furosemide in Treating Pulmonary Edema: A Randomized Controlled Trial
This randomized controlled trial compares intravenous furosemide alone with intravenous plus nebulized furosemide in adults with acute pulmonary edema. The main outcome is the change in peripheral oxygen saturation (SpO2) from baseline, and the secondary outcome is the change in dyspnea severity on a 0-10 visual analogue scale. The trial will test whether adding nebulized furosemide to standard intravenous furosemide gives additional benefit.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Pulmonary edema is a medical emergency in which fluid collects in the alveolar spaces, impairing gas exchange and causing respiratory distress. Intravenous furosemide is the mainstay of treatment but may cause hypotension, electrolyte imbalance and renal dysfunction. Nebulized furosemide delivers the drug directly to the lungs and may improve dyspnea and oxygenation through local effects. Most available studies have tested nebulized furosemide as an alternative to intravenous therapy rather than as an adjunct, so it remains unclear whether the combination offers added benefit over intravenous furosemide alone.
Methods: A randomized controlled trial will be conducted in the Department of Medicine, Federal Government Polyclinic Hospital, Islamabad, over 6 months after ethical approval, using non-probability consecutive sampling. A total of 130 patients (65 per group) will be enrolled. Sample size was calculated with the WHO formula for two means (alpha 0.05, power 80%, SD 1.5, expected difference 0.7) based on Barzegari et al. (2021). After written informed consent, baseline demographics, vital signs, SpO2 and dyspnea VAS score will be recorded. All patients will receive standard initial care with oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg. Patients will be randomized 1:1 using a computer-generated sequence with sequentially numbered, opaque, sealed envelopes. Group A will receive intravenous furosemide 1 mg/kg plus nebulized furosemide 40 mg in 4 ml 0.9% saline, and Group B will receive intravenous furosemide 1 mg/kg alone. SpO2 and dyspnea VAS will be recorded at baseline and at 30, 60 and 120 minutes after intervention.
Statistical analysis: Data will be analyzed in SPSS version 23. Continuous variables will be presented as mean and standard deviation. Between-group comparison of change from baseline in SpO2 and VAS will be done with the independent samples t-test, or the Mann-Whitney U test for non-normal data. Baseline SpO2, baseline dyspnea score, oxygen flow rate, use of nitrates or morphine and underlying cardiac function will be recorded as potential confounders. A p-value below 0.05 will be considered significant.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studiekontakt
- Namn: Tausif Khan
- Telefonnummer: +923110920949
- E-post: mtausifkhan1999@gmail.com
Studieorter
-
-
Islamabad
-
Islamabad, Islamabad, Pakistan, 44000
- Department of Medicine, Federal Government Polyclinic Hospital
-
Huvudutredare:
- Tausif Khan
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adults aged 18 to 94 years
- Acute shortness of breath within the past 6 hours
- Clinical features of pulmonary edema (tachypnea, use of accessory muscles, crepitations, wheeze, gallop rhythm) with chest X-ray showing bilateral pulmonary infiltrates consistent with pulmonary edema, with or without cardiomegaly, pulmonary vascular congestion, Kerley B lines or pleural effusion
Exclusion Criteria:
- Cardiogenic shock or systolic blood pressure below 90 mm Hg
- Need for intubation, cardiac arrhythmia or liver failure
- COPD or asthma exacerbation
- End-stage renal disease on dialysis
- Allergy to furosemide
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Group A: IV plus nebulized furosemide
Intravenous furosemide 1 mg/kg slow push over 5 minutes plus nebulized furosemide 40 mg diluted in 4 ml 0.9% saline over 15 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg). |
Furosemide 40 mg diluted in 4 ml 0.9% saline given by jet nebulizer over 15 minutes.
Andra namn:
Furosemide 1 mg/kg given as a slow intravenous push over 5 minutes.
Andra namn:
|
|
Aktiv komparator: Group B: IV furosemide
Intravenous furosemide 1 mg/kg slow push over 5 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg). |
Furosemide 1 mg/kg given as a slow intravenous push over 5 minutes.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in peripheral oxygen saturation (SpO2)
Tidsram: Baseline, 30, 60 and 120 minutes after intervention (primary comparison at 60 minutes)
|
SpO2 (%) measured with a calibrated pulse oximeter; change from baseline will be compared between groups. |
Baseline, 30, 60 and 120 minutes after intervention (primary comparison at 60 minutes)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in dyspnea severity on Visual Analogue Scale (VAS)
Tidsram: Baseline, 30, 60 and 120 minutes after intervention
|
Patient-rated breathlessness on a 0-10 VAS (0 = no breathlessness, 10 = worst breathlessness); change from baseline will be compared between groups. |
Baseline, 30, 60 and 120 minutes after intervention
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Tausif Khan, MBBS, FCPS Trainee, Federal Government Polyclinic Hospital, Islamabad
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- FGPC-PGMI-MED-2026-PE01
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .